Table 2 Baseline characteristics.

From: Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer

Characteristics

MMR-proficient (n = 949)

MMR-deficient (n = 66)

NCT (n = 403)

NCRT (n = 546)

P value#

NCT (n = 21)

NCRT (n = 45)

P value#

Age (year, %)

  

0.538

  

0.746

 ≤60

244 (60.5)

326 (59.7)

 

18 (85.7)

36 (80.0)

 

 >60

159 (39.5)

220 (40.3)

 

3 (14.3)

9 (20.0)

 

Sex (%)

  

0.419

  

0.771

 Male

283 (70.2)

370 (67.8)

 

14 (66.7)

33 (73.3)

 

BMI

  

0.574

  

0.741

 Mean (SD)

22.4 (3.4)

22.5 (3.0)

 

21.8 (2.8)

22.0 (3.1)

 

Comorbidity (%)

  

0.806

  

0.738

 Yes

91 (22.6)

127 (23.3)

 

3 (14.3)

9 (20)

 

Clinical T stage (%)

  

0.006*

  

0.356

 T1

1 (0.2)

0 (0)

 

0 (0)

0 (0)

 

 T2

6 (1.5)

9 (1.6)

 

1 (4.8)

0 (0)

 

 T3

324 (80.4)

393 (72.0)

 

13 (61.9)

31 (68.9)

 

 T4

72 (17.9)

144 (26.4)

 

7 (33.3)

14 (31.1)

 

Clinical N stage (%)

  

0.058

  

0.089

 N0

100 (24.8)

107 (19.6)

 

2 (9.5)

14 (31.1)

 

 N1

184 (45.7)

289 (52.9)

 

13 (61.9)

17 (37.8)

 

 N2

119 (29.5)

150 (27.5)

 

6 (28.6)

14 (31.1)

 

Clinical stage (%)

  

0.039*

  

0.07

 II

100 (24.8)

107 (19.6)

 

2 (9.5)

14 (31.1)

 

 III

303 (75.2)

439 (80.4)

 

19 (90.5)

31 (68.9)

 

Distance from anal verge (%)

  

<0.001*

  

0.395

 ≤5 cm

164 (40.7)

278 (50.9)

 

10 (47.6)

28 (62.2)

 

 >5 and ≤10 cm

198 (49.1)

255 (46.7)

 

10 (47.6)

13 (28.9)

 

 >10 cm

41 (10.2)

13 (2.4)

 

1 (4.8)

4 (8.9)

 

ypStage (%)

  

0.018*

  

0.759

 0–I

118 (29.3)

200 (36.6)

 

6 (28.6)

10 (22.2)

 

 II–III

285 (70.7)

346 (63.4)

 

15 (71.4)

35 (77.8)

 

pCR (%)

14 (3.5)

46 (8.4)

0.002*

2 (10.0)

4 (9.0)

0.639

Downstaging status (%)

  

0.003*

  

0.163

 Downstaged

266 (66.0)

409 (74.9)

 

17 (81.0)

28 (62.2)

 

 Same or higher

137 (34.0)

137 (25.1)

 

4 (19.0)

17 (37.8)

 

NAR score

  

<0.001*

  

0.53

 Mean (SD)

21.8 (28.3)

18.1 (26.4)

 

14.8 (8.6)

32.7 (44.4)

 

Differentiation (%)

  

<0.001*

  

0.426

 Well

93 (23.1)

74 (13.6)

 

8 (38.1)

9 (20.0)

 

 Moderately

265 (65.8)

387 (70.9)

 

10 (47.6)

26 (57.8)

 

 Poorly

40 (9.9)

65 (11.9)

 

3 (14.3)

8 (17.8)

 

 NS

5 (1.2)

20 (3.7)

 

0 (0)

2 (4.4)

 
  1. MMR mismatch repair, SD standard deviation, BMI body mass index, NCT neoadjuvant chemotherapy, NCRT neoadjuvant chemoradiotherapy, pCR pathologic complete response, NAR score neoadjuvant rectal score, NS not sure, 5FU 5-fluorouracil, FOLFOX 5-fluorouracil+oxaliplatin, XELOX xeloda+ oxaliplatin, FOLFOXIRI 5-fluorouracil+oxaliplatin+irinotecan.
  2. #Clinicopathological differences between the pMMR and dMMR groups stratified by neoadjuvant treatment groups were compared with the Mann–Whitney U test for continuous variables and χ2 test (or Fisher’s exact test, if appropriate) for categorical data.
  3. *Statistically significant.
Back to article page